GeoVax Labs, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- GeoVax Labs, Inc. is a clinical-stage biotechnology company specializing in the development of vaccines and immunotherapies against infectious diseases and solid tumor cancers. Its core products and services utilize a proprietary modified vaccinia Ankara virus-like particle (MVA-VLP) vaccine platform. The company’s product pipeline includes preventive vaccines targeting COVID-19 (GEO-CM04S1, currently in Phase 2 clinical trials), Mpox (monkeypox) and smallpox, hemorrhagic fever viruses such as Ebola Zaire, Ebola Sudan, and Marburg, malaria, Zika virus, and human immunodeficiency virus (HIV). Additionally, GeoVax develops therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers, with its lead oncology candidate Gedeptin® undergoing Phase 1/2 clinical trials for advanced head and neck squamous cell carcinoma. The company is also advancing GEO-CM02, a pan-coronavirus vaccine candidate. GeoVax operates primarily in the United States, headquartered in Atlanta, Georgia, and has been advancing its clinical pipeline through substantial collaborations and funding. Founded in 2001, the company has recently secured a significant strategic partnership with BARDA through the Project NextGen program, receiving nearly $400 million to support a large-scale Phase 2b clinical trial of GEO-CM04S1, targeting high-risk and immunocompromised populations. In 2024, GeoVax successfully manufactured a clinical batch of its GEO-MVA vaccine candidate for Mpox under current Good Manufacturing Practice (cGMP) standards and plans to initiate clinical evaluation by late 2025. The company is actively pursuing additional strategic partnerships with governments, NGOs, and private-sector stakeholders to enhance the reach and impact of its vaccine technology. Furthermore, GeoVax plans to initiate a Phase 2 clinical trial of Gedeptin in combination with immune checkpoint inhibitors for recurrent head and neck cancer in 2025. The company's advanced MVA manufacturing process aims to provide scalable and cost-effective vaccine production, reinforcing domestic biosecurity by reducing reliance on foreign manufacturers. Overall, GeoVax Labs focuses on innovative vaccine and immunotherapy solutions addressing unmet medical needs in infectious diseases and oncology, with a diversified pipeline progressing through clinical stages and supported by substantial government funding and strategic collaborations.
GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript
GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy
GeoVax Labs (NASDAQ:GOVX) Shares Up 21.1% – Should You Buy?
GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript
GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?
GeoVax Labs Revenue Doubles in Q2
GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript
GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital
GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
3 Penny Stocks Ready to Break Out in 2025
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GeoVax to Participate in Upcoming Investor Conferences in September
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market